BJA Advance Access originally published online on July 23, 2007
British Journal of Anaesthesia 2007 99(3):316-328; doi:10.1093/bja/aem209
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction
1 Department of Anaesthesiology
2 Department of Cardiology, University Hospital Lausanne (CHUV), CH-1011 Lausanne, Switzerland
3 Institute of Anaesthesiology, University Hospital Zürich (USZ), CH-8091 Zürich, Switzerland
* Corresponding author. E-mail: pierre-guy.chassot{at}chuv.ch
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal is much higher than that of surgical bleeding if they are continued. In secondary prevention, aspirin is a lifelong therapy and should never be stopped. Clopidogrel is regarded as mandatory until the coronary stents are fully endothelialized, which takes 3 months for bare metal stents, but up to 1 yr for drug-eluting stents. Therefore, interruption of antiplatelet therapy 10 days before surgery should be revised. After reviewing the data on the use of antiplatelet drugs in cardiology and in surgery, we propose an algorithm for the management of patients, based on the risk of myocardial ischaemia and death compared with that of bleeding, for different types of surgery. Even if large prospective studies with a high degree of evidence are still lacking on different antiplatelet regimens during non-cardiac surgery, we propose that, apart from low coronary risk situations, patients on antiplatelet drugs should continue their treatment throughout surgery, except when bleeding might occur in a closed space. A therapeutic bridge with shorter-acting antiplatelet drugs may be considered.
Keywords: complications, haemorrhage; complications, myocardial infarction; coronary stenosis, drug therapy; platelet aggregation inhibitors, therapeutic use; surgery, non-cardiac
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. K. Tempe, G. Godet, and (on behalf of the authors) Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery Br. J. Anaesth., August 1, 2008; 101(2): 282 - 282. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Head and P. Barash Progress Is Precarious Anesth. Analg., August 1, 2008; 107(2): 362 - 364. [Full Text] [PDF]
|
|
|
|
|
|
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: II. Perioperative Considerations and Management Anesth. Analg., August 1, 2008; 107(2): 570 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhatia, H. Nicholls, and G. Howard-Alpe Coronary artery stents and non-cardiac surgery Br. J. Anaesth., January 1, 2008; 100(1): 137 - 138. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Self and G. M. Howard-Alpe Regional anaesthesia in patients treated with aspirin and clopidogrel Br. J. Anaesth., October 1, 2007; 99(4): 594 - 596. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Blood transfusion and major cancer surgery
- William J Fawcett, et al.
- British Journal of Anaesthesia, 20 Nov 2007 [Full text]
- Post-operative management of patients at high risk of MI with uninterrupted Clopidogrel therapy
- Dr Nathaniel M Broughton, et al.
- British Journal of Anaesthesia, 3 Dec 2007 [Full text]